Multi-compound formulations sometimes have higher total volume per dose because they contain more ingredients
Retatrutide is dosed once weekly by subcutaneous injection, titrated in 4-week steps from a 2 mg start through 4, 8 and 12 mg, with 12 mg being the maximum dose tested in the 2023 NEJM Phase 2 trial (24.2% mean weight loss at 48 weeks) [5][2]
Potential side effects of GLP-1s include nausea, vomiting, changes in vision, low blood sugar, and, in rare cases, thyroid cancer
Like this
A, Cumulative food intake (grams) up to 8 h after an acute ICV injection of OXM (0.3, 1, 3, or 10 nmol)
Creating written procedures and ensuring all staff are trained reduces the chance of these errors occurring